What the new Poland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Salomé Adeyemi
Page 3 of 13 of this archive, newest first.
Archive — page 3
243 piecesWhat changing your injection day does to retatrutide exposure, and what it does not
What the pharmacokinetic data supports about dose timing, missed doses and interruption.
What the new Japan guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new South Africa guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new South Korea guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Reading the retatrutide composition data without the press release
The trials measured mass. Nobody measured whether the participants got weaker.
What the new Poland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Canada guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The one randomised trial that combined an incretin with supervised exercise
The older-adult diet-and-exercise trials are the closest analogue to rapid pharmacological weight loss, and they are twenty years old.
The one randomised trial that combined an incretin with supervised exercise
Mass and function are different endpoints and training affects them differently. Most coverage treats them as one.
What the new Norway guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the liraglutide schedule assumes about a person it has never met
The four-week step exists because four to five weeks is approximately how long a once-weekly drug takes to stop rising at a fixed dose. That is a good reason, and it is not…
The upper rungs, ranked by evidence
We looked at what the dose-ranging data supports about going higher, and it is thinner and less flattering than the market assumes.
The mechanism behind the mechanism
The clinical effect profile is almost fully predictable from where the receptor is expressed, which is unusual and useful.
What the new France guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new New Zealand guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The area postrema, and the anatomy of an unwanted effect
Delayed gastric emptying is a mechanism that becomes an adverse effect above a threshold. It is not a complication in the ordinary sense.
What the new Sweden guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Norway guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Ireland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.